Abatacept in the treatment of lupus

Bibliography

• Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004;20(5):539-50
   PubMed Web of Science ®Google Scholar
• Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996;335(18):1369-77
   PubMed Web of Science ®Google Scholar
• Tsokos GC, Liossis SN. Immune cell signaling defects in lupus: activation, anergy and death. Immunol Today 1999;20(18):119-24
   PubMedGoogle Scholar
• Kammer GM. Immunotherapy tackles lupus. Nat Med 2002;8(12):1356-8
   PubMed Web of Science ®Google Scholar
• Foell J, Mittler RS. Costimulatory molecules as immunotherapeutic targets in systemic lupus erythematosus. Springer Semin Immunopathol 2006;28(2):153-62
   PubMed Web of Science ®Google Scholar
• Wiesendanger M, Stanevsky A, Kovsky S, Diamond B. Novel therapeutics for systemic lupus erythematosus. Curr Opin Rheumatol 2006;18(3):227-35
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174(3):561-9
   PubMed Web of Science ®Google Scholar
• Moreland LW, Alten R, Van den Bosch F, Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheumatism 2002;46(6):1470-9
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M, Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349(20):1907-15
   PubMed Web of Science ®Google Scholar
• Grammer AC, Lipsky PE. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002;46(6):1417-29
   PubMed Web of Science ®Google Scholar
• Vogelzang A, McGuire HM, Yu D, A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008;29(1):127-37
   PubMed Web of Science ®Google Scholar
• Bauquet AT, Jin H, Paterson AM, The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol 2009;10(2):167-75
   PubMed Web of Science ®Google Scholar
• Huang W, Sinha J, Newman J, The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002;46(6):1554-62
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC, Merrill JT, IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46(12):3251-8
   PubMed Web of Science ®Google Scholar
• Sidiropoulos P, Boumpas D. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004;13(5):391-7
   PubMed Web of Science ®Google Scholar
• Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265(5176):1225-7
   PubMed Web of Science ®Google Scholar
• Andrews BS, Eisenberg RA, Theofilopoulos AN, Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 1978;148(5):1198-215
   PubMed Web of Science ®Google Scholar
• Anders H, Schlondorff D. Murine models of renal disease: possibilities and problems in studies using mutant mice. Exp Nephrol 2000;8(4-5):181-93
   PubMedGoogle Scholar
• Davidson A, Aranow C. Lupus nephritis: lessons from murine models. Nature Publishing Group 2010;6(1):13-20
   Google Scholar
• Chu EB, Hobbs MV, Wilson CB, Intervention of CD4 + cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. J Immunol 1996;156(3):1262-8
   PubMed Web of Science ®Google Scholar
• Mihara M, Tan I, Chuzhin Y, CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106(1):91-101
   PubMed Web of Science ®Google Scholar
• Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166(5):2913-16
   PubMed Web of Science ®Google Scholar
• Orencia approved for rheumatoid arthritis. Health News 2006;12(3):2
   Google Scholar
• Kremer JM, Dougados M, Emery P, Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(8):2263-71
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144(12):865-76
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58(4):953-63
   PubMed Web of Science ®Google Scholar
• Kremer JM, Russell AS, Emery P, Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011;70(10):1826-30
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker J-C, Schiff M, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-23
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Combe B, Covucci A, Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54(9):2807-16
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):CD008794
   PubMed Web of Science ®Google Scholar
• Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009;68(1):25-32
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P, Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62(6):1792-802
   PubMed Web of Science ®Google Scholar
• Mease P, Genovese MC, Gladstein G, Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63(4):939-48
   PubMed Web of Science ®Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62(10):3077-87
   PubMed Web of Science ®Google Scholar
• Gordon C. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42(11):1372-9
   PubMed Web of Science ®Google Scholar
• Yee C-S, Isenberg DA, Prabu A, BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis 2008;67(6):873-6
   PubMed Web of Science ®Google Scholar
• Wofsy D, Hillson JL, Diamond B. Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Liang MH, Schur PH, Renal disease subcommittee of the American College of Rheumatology ad hoc committee on systemic lupus erythematosus response criteria, The American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54(2):421-32
   PubMed Web of Science ®Google Scholar
• Dooley MA, Jayne D, Ginzler EM, Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365(20):1886-95
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64(4):1215-26
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61(9):1168-78
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9767):721-31
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(12):3918-30
   PubMed Web of Science ®Google Scholar
• Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34(8):937-44
   PubMed Web of Science ®Google Scholar
• Weiss JE, Sison CP, Ilowite NT, Flares in pediatric systemic lupus erythematosus. J Rheumatol 2007;34(6):1341-4
   PubMed Web of Science ®Google Scholar
• Laustrup H, Voss A, Green A, Junker P. SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study. Lupus 2010;19(3):239-46
   PubMed Web of Science ®Google Scholar
• Nossent J, Kiss E, Rozman B, Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19(8):949-56
   PubMed Web of Science ®Google Scholar
• Strand V. Clinical trial design in systemic lupus erythematosus: lessons learned and future directions. Lupus 200 4;13(5):406-11
   PubMed Web of Science ®Google Scholar